Intralesional immunotherapy as a strategy to treat melanoma

References

• Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res. 2000;10:81–92.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Addeo R, Cartenì G, et al. The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. J Transl Med. 2014;12:291. doi:10.1186/s12967-014-0291-1.
   PubMed Web of Science ®Google Scholar
• Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10:292–303. doi:10.1038/sj.gt.3301885.
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27:5763–5771. doi:10.1200/JCO.2009.24.3675.
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658–670. doi:10.1038/nbt.2287.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–2788. doi:10.1200/JCO.2014.58.3377.
   PubMed Web of Science ®Google Scholar
• Weide B, Derhovanessian E, Pflugfelder A, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer. 2010;116:4139–4146. doi:10.1002/cncr.25156.
   PubMed Web of Science ®Google Scholar
• Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res. 2008;18:405–411. doi:10.1097/CMR.0b013e32831328c7.
   PubMed Web of Science ®Google Scholar
• Campana LG, Valpione S, Mocellin S, et al. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg. 2012;99:821–830. doi:10.1002/bjs.8749.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Milhem MM, Andtbacka RHI, et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. ASCO Meet Abstr. 2014;32:9029.
   Google Scholar
• Garrido C, Paco L, Romero I, et al. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis. 2012;33:687–693. doi:10.1093/carcin/bgr318.
   PubMed Web of Science ®Google Scholar
• Hersey P, Gallagher S. Intralesional immunotherapy for melanoma. J Surg Oncol. 2014;109:320–326. doi:10.1002/jso.23494.
   PubMed Web of Science ®Google Scholar
• Sloot S, Rashid OM, Zager JS. Intralesional therapy for metastatic melanoma. Expert Opin Pharmacother. 2014;15:2629–2639. doi:10.1517/14656566.2014.967682.
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Richards J, Kharkevitch D, et al. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res. 2010;20:218–226. doi:10.1097/CMR.0b013e3283390711.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep. 2007;8:1142–1148. doi:10.1038/sj.embor.7401099.
   PubMed Web of Science ®Google Scholar
• Leonard WJ, Depper JM, Crabtree GR, et al. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature. 1984;311:626–631.
   PubMed Web of Science ®Google Scholar
• Nikaido T, Shimizu A, Ishida N, et al. Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature. 1984;311:631–635.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Matsui H, Fujita T, et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983;302:305–310.
   PubMed Web of Science ®Google Scholar
• Dehesa LA, Vilar-Alejo J, Valerón-Almazán P, et al. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2]. Actas Dermosifiliogr. 2009;100:571–585.
   PubMedGoogle Scholar
• Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer. 2003;89:1620–1626. doi:10.1038/sj.bjc.6601320.
   PubMed Web of Science ®Google Scholar
• Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunotherapy. 2005;28:120–128.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–2116.
   PubMed Web of Science ®Google Scholar
• Shi VY, Tran K, Patel F, et al. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. J Am Acad Dermatol. 2015;73:645–654. doi:10.1016/j.jaad.2015.06.060.
   PubMed Web of Science ®Google Scholar
• Delprat GD, Epstein NN, Kerr WJ. A new liver function test: the elimination of Rose Bengal when injected into the circulation of human subjects. Arch Intern Med. 1924;34:533–541. doi:10.1001/archinte.1924.00120040119011.
   Google Scholar
• Marsh RJ, Fraunfelder FT, McGill JI. Herpetic corneal epithelial disease. Arch Ophthalmol. 1976;94:1899–1902.
   PubMedGoogle Scholar
• Agarwala SS. Intralesional therapy for advanced melanoma: promise and limitation. Curr Opin Oncol. 2015;27:151–156. doi:10.1097/CCO.0000000000000158.
   Google Scholar
• Ross MI. Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma. J Surg Oncol. 2014;109:314–319. doi:10.1002/jso.23554.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216.
   PubMed Web of Science ®Google Scholar
• Thompson JF, Agarwala SS, Smithers BM, et al. Wachter EA: phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol. 2015;22:2135–2142. doi:10.1245/s10434-014-4169-5.
   PubMed Web of Science ®Google Scholar
• Mir LM, Glass LF, Sersa G, et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer. 1998;77:2336–2342.
   PubMed Web of Science ®Google Scholar
• Mali B, Jarm T, Snoj M, et al. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol. 2013;39:4–16. doi:10.1016/j.ejso.2012.08.016.
   PubMed Web of Science ®Google Scholar
• Campana LG, Mocellin S, Basso M, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol. 2009;16:191–199. doi:10.1245/s10434-008-0204-8.
   PubMed Web of Science ®Google Scholar
• Byrne CM, Thompson JF, Johnston H, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res. 2005;15:45–51.
   PubMed Web of Science ®Google Scholar
• Gaudy C, Richard M-A, Folchetti G, et al. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg. 2006;10:115–121.
   PubMed Web of Science ®Google Scholar
• Colombo GL, Matteo SD, Mir LM. Cost-effectiveness analysis of electrochemotherapy with the Cliniporatortrade mark vs other methods for the control and treatment of cutaneous and subcutaneous tumors. Ther Clin Risk Manag. 2008;4:541–548.
   PubMedGoogle Scholar
• Quaglino P, Mortera C, Osella-Abate S, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol. 2008;15:2215–2222. doi:10.1245/s10434-008-9976-0.
   PubMed Web of Science ®Google Scholar
• Kaehler KC, Egberts F, Hauschild A. Electrochemotherapy in symptomatic melanoma skin metastases: intraindividual comparison with conventional surgery. Dermatol Surg. 2010;36:1200–1202. doi:10.1111/j.1524-4725.2010.01608.x.
   PubMed Web of Science ®Google Scholar
• Mozzillo N, Caraco C, Mori S, et al. Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. J Transl Med. 2012;10:131. doi:10.1186/1479-5876-10-233.
   PubMed Web of Science ®Google Scholar
• Möller MG, Salwa S, Soden DM, et al. Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. Expert Rev Anticancer Ther. 2009;9:1611–1630. doi:10.1586/era.09.129.
   PubMed Web of Science ®Google Scholar
• Kis E, Oláh J, Ócsai H, et al. Electrochemotherapy of cutaneous metastases of melanoma–a case series study and systematic review of the evidence. Dermatol Surg. 2011;37:816–824. doi:10.1111/j.1524-4725.2011.01951.x.
   PubMed Web of Science ®Google Scholar
• Caracò C, Mozzillo N, Marone U, et al. Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis. BMC Cancer. 2013;13:564. doi:10.1186/1471-2407-13-564.
   PubMed Web of Science ®Google Scholar